Literature DB >> 15076201

Prognostic significance of isolated, non-specific left ventricular repolarization abnormalities in hypertension.

Giuseppe Schillaci1, Matteo Pirro, Leonella Pasqualini, Gaetano Vaudo, Tiziana Ronti, Fabio Gemelli, Simona Marchesi, Gianpaolo Reboldi, Carlo Porcellati, Elmo Mannarino.   

Abstract

OBJECTIVE: Clinicians are often confronted with the incidental finding of isolated minor, non-specific repolarization changes on the electrocardiogram (ECG) in hypertensive patients. The aim of this study was to investigate the prognostic significance of such changes.
DESIGN: Prospective, observational study.
METHODS: A total of 1970 hypertensive patients without prevalent cardiovascular disease were followed for up to 9.1 years (mean 4.7 years). Patients with ECG abnormalities including ischaemia, previous infarction, bundle branch block, atrial fibrillation and ventricular pre-excitation were excluded. Patients were divided into three groups: normal left ventricular (LV) repolarization (n = 1355); minor repolarization changes (n = 504); and typical LV strain (n = 111).
RESULTS: During follow-up, 78 patients developed new-onset ischaemic heart disease. The event rates were 0.50, 1.28 and 3.08 per 100 patient-years in the groups with normal repolarization, minor changes, and typical LV strain, respectively (P < 0.001). After adjustment for the effect of age, sex, diabetes, serum cholesterol, smoking, LV hypertrophy and 24-h pulse pressure, the risk for developing coronary events was higher in patients with minor repolarization changes (hazard ratio 2.07, 95% confidence interval 1.23-3.47; P < 0.01) or LV strain (hazard ratio 4.00, 95% confidence interval 2.09-7.65; P < 0.001) than in patients with normal repolarization (reference category). Population-attributable risks were 21 and 14%, respectively. Minor ST-T changes also retained an adverse prognostic value among patients without LV hypertrophy (hazard ratio 1.90, 95% confidence interval 1.08-3.33; P = 0.026).
CONCLUSION: We have identified minor, non-specific LV repolarization changes as a novel, independent risk factor for ischaemic heart disease in patients with uncomplicated hypertension.

Entities:  

Mesh:

Year:  2004        PMID: 15076201     DOI: 10.1097/00004872-200402000-00027

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  5 in total

1.  Second statement of the working group on electrocardiographic diagnosis of left ventricular hypertrophy.

Authors:  Ljuba Bacharova; E Harvey Estes; Lia E Bang; Joseph A Hill; Peter W Macfarlane; Ian Rowlandson; Giuseppe Schillaci
Journal:  J Electrocardiol       Date:  2011-07-14       Impact factor: 1.438

Review 2.  Modulation of the QT interval duration in hypertension with antihypertensive treatment.

Authors:  Jan Klimas; Peter Kruzliak; Simon W Rabkin
Journal:  Hypertens Res       Date:  2015-03-19       Impact factor: 3.872

3.  Measurement of ECG abnormalities and cardiovascular risk classification: a cohort study of primary care patients in the Netherlands.

Authors:  Anne Groot; Michiel L Bots; Frans H Rutten; Hester M den Ruijter; Mattijs E Numans; Ilonca Vaartjes
Journal:  Br J Gen Pract       Date:  2015-01       Impact factor: 5.386

4.  Prognostic value of non-specific ST-T changes and left ventricular hypertrophy electrocardiographic criteria in hypertensive patients: 16-year follow-up results from the MINACOR cohort.

Authors:  Ernest Vinyoles; Núria Soldevila; Joan Torras; Noemí Olona; Mariano de la Figuera
Journal:  BMC Cardiovasc Disord       Date:  2015-03-18       Impact factor: 2.298

5.  Electrocardiographic Strain Pattern Is Associated With Left Ventricular Concentric Remodeling, Scar, and Mortality Over 10 Years: The Multi-Ethnic Study of Atherosclerosis.

Authors:  Yuko Y Inoue; Elsayed Z Soliman; Kihei Yoneyama; Bharath Ambale-Venkatesh; Colin O Wu; Rodney Sparapani; David A Bluemke; João A C Lima; Hiroshi Ashikaga
Journal:  J Am Heart Assoc       Date:  2017-09-20       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.